Ligand id: 9615

Name: ALT-803

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
No information available.
Summary of Clinical Use
As of 25 July 2017, had 28 registered trials involving ALT-803 (link to the list here), only one of which is Phase 2/3 (NCT03022825). ALT-803 is being evaluated across a range of solid and liquid tumours.
Mechanism Of Action and Pharmacodynamic Effects
IL-15 is a cytokine critical for the development, proliferation and activation of effector natural killer (NK) cells and CD8+ memory T cells, but its clinical utility is limited by its short in vivo half-life, and is technically difficult to produce. ALT-803 was developed as an IL-15 mimetic superagonist to overcome these problems. ALT-803 promotes robust and antigen-independent activity in various tumor models, and is predicted to synergistically enhance the efficacy of other cancer drugs against solid tumours and hematological malignancies.